These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10331824)

  • 1. Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.
    Kovacs SJ; Tenero DM; Martin DE; Ilson BE; Jorkasky DK
    Pharmacotherapy; 1999 May; 19(5):612-9. PubMed ID: 10331824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
    Martin DE; Chapelsky MC; Ilson B; Tenero D; Boike SC; Zariffa N; Jorkasky DK
    J Clin Pharmacol; 1998 Feb; 38(2):129-37. PubMed ID: 9549643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.
    Tenero DM; Martin DE; Ilson BE; Boyle DA; Boike SC; Carr AM; Lundberg DE; Jorkasky DK
    Ann Pharmacother; 1998 Mar; 32(3):304-8. PubMed ID: 9533060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan.
    Tenero D; Martin D; Chapelsky M; Ilson B; Boike S; Patterson S; Keogh J; Rodriguez S; Jorkasky D
    Pharmacotherapy; 1998; 18(1):42-50. PubMed ID: 9469680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of age and gender on the pharmacokinetics of eprosartan.
    Tenero DM; Martin DE; Miller AK; Ilson B; Boike SC; Zariffa N; Jorkasky DK
    Br J Clin Pharmacol; 1998 Sep; 46(3):267-70. PubMed ID: 9764969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose proportionality study of eprosartan in healthy male volunteers.
    Chapelsky MC; Martin DE; Tenero DM; Ilson BE; Boike SC; Etheredge R; Jorkasky DK
    J Clin Pharmacol; 1998 Jan; 38(1):34-9. PubMed ID: 9597557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and urinary excretion of eprosartan in Chinese healthy volunteers of different gender.
    Xu HR; Chen WL; Li XN; Liu GY; Chu NN; Yu C
    Pharmazie; 2007 Oct; 62(10):782-4. PubMed ID: 18236785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eprosartan.
    McClellan KJ; Balfour JA
    Drugs; 1998 May; 55(5):713-8; discussion 719-20. PubMed ID: 9585867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies.
    Blum RA; Kazierad DJ; Tenero DM
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):79S-85S. PubMed ID: 10213526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations.
    Bottorff MB; Tenero DM
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):73S-78S. PubMed ID: 10213525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.
    Kazierad DJ; Martin DE; Blum RA; Tenero DM; Ilson B; Boike SC; Etheredge R; Jorkasky DK
    Clin Pharmacol Ther; 1997 Oct; 62(4):417-25. PubMed ID: 9357393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food.
    Tenero D; Martin D; Ilson B; Jushchyshyn J; Boike S; Lundberg D; Zariffa N; Boyle D; Jorkasky D
    Biopharm Drug Dispos; 1998 Sep; 19(6):351-6. PubMed ID: 9737815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patients.
    van Rijn-Bikker PC; Ackaert O; Snelder N; van Hest RM; Ploeger BA; Koopmans RP; Mathôt RA
    Clin Pharmacokinet; 2013 Sep; 52(9):793-803. PubMed ID: 23696281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eprosartan: a review of its use in the management of hypertension.
    Plosker GL; Foster RH
    Drugs; 2000 Jul; 60(1):177-201. PubMed ID: 10929934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.
    Martin DE; Tompson D; Boike SC; Tenero D; Ilson B; Citerone D; Jorkasky DK
    Br J Clin Pharmacol; 1997 Jun; 43(6):661-4. PubMed ID: 9205830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of eprosartan in combination with hydrochlorothiazide.
    Böhm M; Sachse A
    Drug Saf; 2002; 25(8):599-611. PubMed ID: 12113644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of eprosartan.
    Gavras I; Gavras H
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):102S-107S. PubMed ID: 10213529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.
    Martin DE; DeCherney GS; Ilson BE; Jones BA; Boike SC; Freed MI; Jorkasky DK
    J Clin Pharmacol; 1997 Feb; 37(2):155-9. PubMed ID: 9055142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The renal profile of eprosartan.
    Sica DA; Hollenberg NK
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):86S-94S. PubMed ID: 10213527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.